Bioerg Spólka Akcyjna Valuation
Is BER undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BER when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate BER's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate BER's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BER?
Other financial metrics that can be useful for relative valuation.
What is BER's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | zł13.78m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 45x |
Enterprise Value/EBITDA | -363.6x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does BER's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 16.7x | ||
GX1 genXone | 9.6x | n/a | zł23.1m |
SCS Stem Cells Spin | 48.9x | n/a | zł20.5m |
GEN Genomed Spólka Akcyjna | 1.7x | n/a | zł39.1m |
RDG Read-Gene | 6.5x | n/a | zł65.3m |
BER Bioerg Spólka Akcyjna | 46.1x | n/a | zł13.8m |
Price-To-Sales vs Peers: BER is expensive based on its Price-To-Sales Ratio (46.1x) compared to the peer average (16.6x).
Price to Earnings Ratio vs Industry
How does BER's PE Ratio compare vs other companies in the European Biotechs Industry?
Price-To-Sales vs Industry: BER is expensive based on its Price-To-Sales Ratio (46.1x) compared to the European Biotechs industry average (8x).
Price to Sales Ratio vs Fair Ratio
What is BER's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 46.1x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate BER's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.